Interleukin-13

Dupilumab significantly improved atopic dermatitis signs, symptoms and quality of life in Asian, black and white patients, according to a pooled analysis of three phase 3 trials.

Dupilumab showed consistent and sustained efficacy in an open-label extension study in adults previously enrolled in 12 parent studies assessing dupilumab in moderate to severe atopic dermatitis.

Children aged 6 to 11 years with severe atopic dermatitis assigned dupilumab and topical corticosteroids significantly improved in measures of overall disease severity, skin clearing, itching and health-related quality of life vs. topical corticosteroids alone in a phase 3 trial.

NEW YORK — There are now multiple target treatments to utilize in patients with atopic dermatitis, but there is still a very large unmet need for better treatment in this disease, according to Emma Guttman-Yassky, MD, PhD, a Sol and Clara Kest professor of dermatology at Icahn School of Medicine at Mount Sinai in New York.